Pricing Log in Create free account

NextCure, Inc. (NXTC) vs TransCode Therapeutics Inc. (RNAZ)

NextCure, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. NextCure, Inc. and TransCode Therapeutics Inc. are of similar size ($31.5M and $30.5M). Across the 7 metrics below, TransCode Therapeutics Inc. leads on 4 and NextCure, Inc. on 3.

Valuation

Metric NXTC RNAZ Biotechnology median
P/E n/m n/m 8.50
P/S 1.21 n/m 9.71
P/B 2.73 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales 0.57 n/m 9.21
Earnings yield (139.42%) (3,080.59%) (33.15%)
Free cash flow yield (113.06%) (1,390.70%) (25.50%)

Profitability

Metric NXTC RNAZ Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (195.22%) 429.61% (56.36%)
Return on assets (121.60%) (58.12%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric NXTC RNAZ Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 17.75% 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NXTC RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.47 1.97 4.72
Net debt to EBITDA 0.75 0.64 0.96

Dividend

Metric NXTC RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NXTC RNAZ Biotechnology median
Market cap 31.49m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack